Last reviewed · How we verify

Bupivacaine 0.5% — Competitive Intelligence Brief

Bupivacaine 0.5% (Bupivacaine 0.5%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic (amide class). Area: Anesthesia.

marketed Local anesthetic (amide class) Voltage-gated sodium channels Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

Bupivacaine 0.5% (Bupivacaine 0.5%) — Kasr El Aini Hospital. Bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of nerve impulses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Bupivacaine 0.5% TARGET Bupivacaine 0.5% Kasr El Aini Hospital marketed Local anesthetic (amide class) Voltage-gated sodium channels
Lidocaïne Lidocaïne University Hospital, Angers marketed Local anesthetic Voltage-gated sodium channels
Hydrocortisone acetate and lidocaine hydrochloride Hydrocortisone acetate and lidocaine hydrochloride Citius Pharmaceuticals, Inc. marketed Topical corticosteroid and local anesthetic combination Glucocorticoid receptor (hydrocortisone); voltage-gated sodium channels (lidocaine)
Lidocaine alone Lidocaine alone TriHealth Inc. marketed Local anesthetic Voltage-gated sodium channels
lidocaine and sufentanil lidocaine and sufentanil RenJi Hospital marketed Local anesthetic and opioid analgesic combination Voltage-gated sodium channels (lidocaine); mu opioid receptor (sufentanil)
Low-Dose Lidocaine Low-Dose Lidocaine The Methodist Hospital Research Institute marketed Local anesthetic / sodium channel blocker Voltage-gated sodium channels
Naropeine (Ropivacaine) Naropeine (Ropivacaine) Nantes University Hospital marketed Local anesthetic (amide) Voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic (amide class) class)

  1. Ain Shams University · 2 drugs in this class
  2. Başakşehir Çam & Sakura City Hospital · 2 drugs in this class
  3. TriHealth Inc. · 2 drugs in this class
  4. Centre of Postgraduate Medical Education · 2 drugs in this class
  5. Bozyaka Training and Research Hospital · 2 drugs in this class
  6. Complejo Hospitalario Universitario de Granada · 1 drug in this class
  7. Clinique Saint-Jean, Bruxelles · 1 drug in this class
  8. Hospital Clínico Universitario de Valencia · 1 drug in this class
  9. Fundacion Clinica Valle del Lili · 1 drug in this class
  10. Federal University of Minas Gerais · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bupivacaine 0.5% — Competitive Intelligence Brief. https://druglandscape.com/ci/bupivacaine-0-5. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: